CD274 and non-small cell lung carcinoma: In particular, some programmed cell death 1 (PD‐1)/programmed cell death‐ligand 1 (PD‐L1) inhibitors have been clinically available for medical therapy of non‐small cell lung cancer (NSCLC) patients.1, 2